Physician profile
Robert C Barnes
NPI 1316961360
$2,174.45
in general payments reported to CMS, 2019-2025
26 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $102 · 2021: $526 · 2022: $417 · 2023: $256 · 2024: $380 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.91 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $661.19 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $341.43 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $237.11 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $170.62 | 2019-2025 | Veozah |
| Abbvie INC. | $159.79 | 2020-2025 | |
| Pfizer INC. | $97.42 | 2022-2025 | |
| Exact Sciences Corporation | $71.64 | 2024-2025 | Cologuard Collection Kit |
| Philips North America LLC | $70.72 | 2023-2025 | (8874) Incourage, Vest Therapy Und |
| Nestle Healthcare Nutrition INC. | $54.09 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $29.40 | 2021 | |
| Amarin Pharma, INC. | $24.72 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $24.43 | 2021-2022 | |
| Abbott Laboratories | $24.36 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $22.19 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.28 | 2024 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $18.40 | 2022 | |
| Daiichi Sankyo INC. | $17.27 | 2025 | Injectafer |
| Ibsa Pharma INC. | $16.56 | 2022 | |
| Merck Sharp & Dohme LLC | $15.28 | 2024 | Gardasil, Vaxelis, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2023 | Gattex |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.98 | 2025 | Caplyta |
| Ars Pharmaceuticals Operations, INC. | $14.94 | 2025 | Neffy |
| Avanir Pharmaceuticals, INC. | $13.96 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.62 | 2021 | |
| Glaxosmithkline, LLC. | $12.36 | 2022 | |
| Allergan, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.